



Roma, 9-12 novembre 2017



ITALIAN CHAPTER



TRUST Study «la difesa»

Dott. Roberto Negro
U.O. Endocrinologia
P.O. «V Fazzi» Lecce



Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism

Roma, 9-12 novembre 2017



ITALIAN CHAPTER

- «...treatment with levothyroxine in older persons with subclinical hypothyroidism provided no symptomatic benefits»




Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism

Roma, 9-12 novembre 2017



ITALIAN CHAPTER

- Disegno dello studio: trial multicentrico, doppio-cieco, randomizzato, placebo-controllo, gruppi paralleli





Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism

Roma, 9-12 novembre 2017



ITALIAN CHAPTER

- Questionario ThyPRO: validato*

*

1. Rasmussen SL: Eur Thyroid J 2016
2. Wong CK: J Clin Epidemiol 2016
3. Watt T: Health Qual Life Outcomes 2014
4. Watt T: Qual Life Res 2014
5. Watt T: J Clin Endocrinol Metab: 2014
6. Watt T: Eur J Endocrinol 2010
7. Watt T: Qual Life Res: 2009)




Roma, 9-12 novembre 2017

Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism



ITALIAN CHAPTER

- Differenza TSH: persistente (1.9mIU/L)





Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism

Roma, 9-12 novembre 2017



ITALIAN CHAPTER

- The two primary outcomes were changes in two domains (**hypothyroid symptoms** and **tiredness score**) on the thyroid-related quality of life questionnaire (ThyPRO) at one year
- Secondary outcomes include general **health-related quality of life** (EuroQol)




Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism



Roma, 9-12 novembre 2017

- Per l'outcome primario: il numero richiesto considerato statisticamente significativo era **750** pazienti considerando una variazione del 3.0% “Hypothyroid Symptoms”, e del 4.1% “Tiredness score”; **540** pazienti considerando una variazione del 3.5% per “Hypothyroid Symptoms” e del 4.9% per “Tiredness score”.
- Inoltre, per “compensare” i drop-out sono state utilizzate correzioni statistiche (“modified intention-to-treat analysis” e “multiple imputations for missing data”)






Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism

Roma, 9-12 novembre 2017




ITALIAN CHAPTER

Hypothyroidism Symptoms Score



Tiredness Score







Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism



ITALIAN CHAPTER

Health Related Quality of Life





6-Month Treatment with LT4



ITALIAN CHAPTER


Roma, 9-12 novembre 2017

63 patients


Age: 47 y (median)

TSH: 8.1 mIU/L (median)

ThyPRO radar plot



SF-36 Radar plot





Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism

Roma, 9-12 novembre 2017



ITALIAN CHAPTER

Secondary outcomes

- *Hand-grip strength (dynamometer)*
- *Executive cognitive functions (letter-digit coding test)*
- *Blood pressure*
- *Weight*
- *BMI*
- *Waist circumference*
- *Activities of daily living (Barthel Index)*
- *Instrumental activities of daily living score*
- *Fatal and non-fatal cardiovascular events*



Roma, 9-12 novembre 2017



ITALIAN CHAPTER





Hypothyroid Symptoms Fail to Predict Thyroid Insufficiency in Old People: A Population-Based Case-Control Study


538,734 citizens; 140 overt hypo; median TSH: 54.5 mIU/l




ITALIAN CHAPTER

Roma, 9-12 novembre 2017

Mean number of symptoms present at disease onset in autoimmune overt hypothyroidism



ORs for autoimmune overt hypothyroidism in the presence of different number of symptoms






Roma, 9-12 novembre 2017

TSH change across ages




ITALIAN CHAPTER

Longitudinal Change in TSH



NHANES III




- 908 patients
- 13 yr follow up
- TPOAb, TgAb, Drugs: excluded



Roma, 9-12 novembre 2017



ITALIAN CHAPTER





Roma, 9-12 novembre 2017

Cognitive Function in the Elderly



ITALIAN CHAPTER

- 599 participants were followed up from age **85** y through age **89** y
- TSH and FT4 were not associated with disability in daily life, depressive symptoms, and cognitive impairment at baseline or during follow-up
- *Increasing levels of TSH were associated with a lower mortality rate*

Gussekloo J et al. JAMA 2004

- RCT: effect of LT4 in Subclinical Hypothyroidism in 97 patients >65y
- Mini-Mental State; Examination Middlesex Elderly Assessment of Mental State (covering orientation, learning, memory, numeracy, perception, attention, and language skills); Trail-Making A and B
- No significant changes in any of the measures of cognitive function over time and no between-group difference in cognitive scores at 6 and 12 months.

Pearle J et al. J Clin Endocrinol Metab 2010



Roma, 9-12 novembre 2017


Subclinical Thyroid Dysfunction and the Risk of Stroke and Fatal Stroke




ITALIAN CHAPTER

45 573 subjects (3451 subclinical hypo)
from 17 cohorts and followed up from 1972-2014

Stroke events by age



Fatal stroke by age






The Influence of Age on the Relationship between Subclinical Hypothyroidism and Ischemic Heart Disease: A Metaanalysis



ITALIAN CHAPTER

Roma, 9-12 novembre 2017

Cardiovascular mortality in longitudinal studies



- **Objective:** to investigate whether age and gender influence IHD prevalence, incidence, and mortality in people with SCH.
- **Data Synthesis:** There were 15 studies included for analysis with 2,531 SCH participants and 26,491 euthyroid individuals.




The Influence of Age on the Relationship between Subclinical Hypothyroidism and Ischemic Heart Disease: A Metaanalysis




ITALIAN CHAPTER

Roma, 9-12 novembre 2017

IHD prevalence in cross-sectional studies



IHD incidence in longitudinal studies






Subclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular Risk



ITALIAN CHAPTER

Roma, 9-12 novembre 2017

Cumulative incidence of heart failure hospitalization



- The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) is a prospective cohort study
- Patients included men and women aged 70–82 yr ($n = 5316$) with **known cardiovascular risk factors or previous cardiovascular disease**.
- 3.2-yr follow-up period



Levothyroxine Treatment of Subclinical Hypothyroidism, Fatal and Nonfatal Cardiovascular Events, and Mortality



UK General Practitioner Research Database (2001-2009)



ITALIAN CHAPTER

Roma, 9-12 novembre 2017

IHD events (fatal and nonfatal)





Long-Term Outcome in Levothyroxine Treated Patients With Subclinical Hypothyroidism and Concomitant Heart Disease

Roma, 9-12 novembre 2017



ITALIAN CHAPTER

61.611

Patients with cardiac disease

1.192

Subclinical Hypo
(mean age: 74 yr)

136

LT4

1.056

Untreated




Long-Term Outcome in Levothyroxine Treated Patients With Subclinical Hypothyroidism and Concomitant Heart Disease



ITALIAN CHAPTER

Roma, 9-12 novembre 2017



Follow-up time of 5.6 y
694 (58.2%) patients died

Patients treated with LT4: no significant increased risk of all-cause mortality, MACE, or hospital admission

LT4 treatment in patients with SCH and heart disease was not associated with a significant benefit nor risk



Conclusioni



ITALIAN CHAPTER

Roma, 9-12 novembre 2017

- Lo studio è RCT, metodologicamente corretto
- Potenza statistica adeguata per l'outcome primario
- Ha confermato l'assenza di efficacia della terapia sostitutiva nell'anziano con Ipo Subclinico (assenza di «malattia»?)
- Ha confermato precedenti studi sulla inutilità della L-T4 nell'anziano
- Ha indirettamente confermato la necessità di range di riferimento età-specifici